Life Sciences

  • April 16, 2025

    Wyo. Justices Skeptical Of State Abortion Bans' Legality

    The Wyoming Supreme Court on Wednesday seemed poised to side with a lower court judge that recent abortion bans violate the state's constitution, hinting that the Legislature doesn't have the authority to determine when life begins and thus cannot establish a compelling interest for the laws. 

  • April 16, 2025

    Sterlington Adds Ex-Loeb & Loeb PTAB Trials Head In Calif.

    International law firm Sterlington PLLC has added a partner who has guided clients in more than 140 proceedings before the U.S. Patent Trial and Appeal Board, strengthening its intellectual property practice with the former chair of Loeb & Loeb's PTAB trials practice, the firm announced Wednesday.

  • April 16, 2025

    Biotech Glycomine Closes $115M Series C Funding Round

    Biotechnology company Glycomine Inc. on Wednesday announced that it wrapped its Series C funding round with $115 million in tow to advance its lead candidate into a Phase 2b clinical trial.

  • April 16, 2025

    California Challenges Trump's Economic Emergency Tariffs

    The California state government filed suit Wednesday challenging President Donald Trump's recent use of a law that has allowed him to unilaterally impose broad and aggressive tariffs on imports entering the U.S.

  • April 15, 2025

    Astellas Bladder Drug Patent Survives Following Bench Trial

    A Delaware federal judge on Tuesday held that generic-drug makers Lupin and Zydus Pharmaceuticals haven't shown "by clear and convincing evidence" that an Astellas Pharma patent covering the bladder medication Myrbetriq is invalid.

  • April 15, 2025

    Biogen, Genentech Head To June Trial Over MS Drug Royalties

    A California federal judge on Tuesday denied Biogen's bid for summary judgment in a high-stakes contract fight with Roche Holding AG subsidiary Genentech over patent royalties on multiple sclerosis drug sales, saying during a hearing that there's a material dispute over the contract's language and the case will be tried in June.

  • April 15, 2025

    Novo Nordisk Seeks Toss Of Hospital's Insulin Pen Suit

    Novo Nordisk has told a Connecticut federal judge that a hospital in the state didn't show that the pharmaceutical company didn't warn nurses that its insulin pens are meant to be used with only one patient in a suit over a $1 million settlement the hospital paid to patients potentially exposed to blood-borne infections.

  • April 15, 2025

    Fed. Circ. Won't Revive Stryker Unit's Antiseptic Patents

    The Patent Trial and Appeal Board properly invalidated claims in two Sage Products LLC patents for sterilizing antiseptics, the Federal Circuit affirmed Tuesday.

  • April 15, 2025

    39 AGs Urge Congress To Ban PBM Pharmacy Ownership

    A bipartisan coalition of attorneys general have urged congressional leadership to pass legislation banning pharmacy benefit managers, their parent companies and affiliates from owning and operating pharmacies in order to boost competition and fairness.

  • April 15, 2025

    Ga. Woman Says Baby 'Ripped Away' After Embryo Mix-Up

    A South Carolina fertility clinic has been hit with a lawsuit from a former patient alleging that its doctors placed the wrong embryo inside her — a fact she discovered only when she, a white woman, gave birth to a Black boy — only to have the baby "ripped away from her" by his biological parents after months of raising him as her own.

  • April 15, 2025

    Research Co. Inks $7.15M Deal To End Stock Plan Suit

    A genomic research company agreed to pay $7.15 million to resolve a suit claiming it shorted former workers enrolled in an employee stock ownership plan when it required them to sell their shares back to the company, according to filings in Massachusetts federal court.

  • April 15, 2025

    Haleon Paying $221M For Full Control Of Chinese Pharma JV

    British consumer healthcare company Haleon PLC said Tuesday it has agreed to purchase the remaining 12% stake in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co., for 1.623 billion yuan ($221 million) after increasing its stake to 88% last year. 

  • April 15, 2025

    Kirkland-Led Linden Wraps $5.4B Healthcare-Focused Fund

    Healthcare-focused private equity shop Linden Capital Partners, advised by Kirkland & Ellis LLP, on Tuesday announced that it clinched its sixth fund with $5.4 billion of capital commitments.

  • April 14, 2025

    Musk Supports Deleting IP Law, Attorneys Say Let's Not

    Elon Musk's endorsement of a terse social media post from tech executive Jack Dorsey saying "delete all IP law" drew scorn from the intellectual property community and was followed by posts from U.S. Patent and Trademark Office acting Director Coke Morgan Stewart extolling the virtues of trademark, patent and copyright protections.

  • April 14, 2025

    Fed. Circ. Hears Teva Challenge To J&J Schizophrenia Drug

    A Federal Circuit panel on Monday grappled with how to determine whether a dosage patent on Johnson & Johnson's blockbuster schizophrenia drug Invega Sustenna is invalid as obvious, questioning attorneys for the company and generics maker Teva about the proper analysis.

  • April 14, 2025

    Juul Seeks Ax of Noncompliant Plaintiffs In E-Cig Suits

    Juul on Monday asked a California federal judge to toss claims brought by plaintiffs who failed to comply with court orders, about two years after Juul reached a $255 million global settlement in the litigation.

  • April 14, 2025

    Ozempic Pretender On Sale In Conn., Novo Nordisk Says

    A Connecticut company is selling compounded drugs that purport to contain semaglutide, the active ingredient in Novo Nordisk medications including Ozempic, and improperly implying that the products are approved by the U.S. Food and Drug Administration, according to a lawsuit that alleges violations of state and federal law.

  • April 14, 2025

    J&J Units Beat Patent Suit Over Surgical Screw Designs

    A Delaware federal judge has handed Johnson & Johnson subsidiary DePuy Synthes Inc. a win in a patent infringement lawsuit launched by a retired surgeon's patent company over surgical screw technology, finding that the patent claims are too broad and invalid for lack of enablement.

  • April 14, 2025

    Women's Healthtech Co. Chiaro Files Ch. 15 In Delaware

    British women's healthtech company Chiaro Technology Ltd. has filed for Chapter 15 recognition in Delaware bankruptcy court, seeking acknowledgment of an insolvency proceeding in the United Kingdom through which it aims to manage its American assets while pursuing a sale to a competitor.

  • April 14, 2025

    Takeda Gets Actos Case Paused For Class Cert. Review

    A New York federal court has paused a lawsuit accusing Takeda Pharmaceuticals of inflating the price of its diabetes treatment, Actos, by delaying the entry of generic alternatives, and took a scheduled July trial off the calendar, as the company appeals a class certification ruling.

  • April 14, 2025

    Sandoz Sues Amgen Over Enbrel Biosimilar

    Sandoz accused Amgen of illegally blocking biosimilar competition to its blockbuster Enbrel drug for arthritis and other inflammatory diseases, alleging that the company used strategic acquisitions and illegal patent extensions to fend off challengers in the space and inflate U.S. prices for its drug.

  • April 14, 2025

    3 Ex-Cooley IP Attys Help Launch New Fenwick Boston Office

    Fenwick & West LLP said Monday it has opened a temporary office in Boston with three new intellectual property partners, including Matthew Pavao, Cooley LLP's former global patent prosecution and counseling group chair, with plans to open a permanent space in the future.

  • April 11, 2025

    Amgen Can't Ditch Regeneron's Bundling Antitrust Suit

    A Delaware federal judge on Thursday denied Amgen's bid to toss antitrust litigation brought by Regeneron accusing its rival of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market.

  • April 11, 2025

    Express Scripts Judge Asks If Khan's FTC Exit Affects Suit

    The Missouri federal judge overseeing Express Scripts' lawsuit accusing the Federal Trade Commission of defaming it with a report excoriating the pharmacy benefits manager for allegedly inflating drug costs asked the parties Friday if new leadership at the commission affects the case that significantly targets former Chair Lina Khan.

  • April 11, 2025

    Dentsply Brass Face Investor Suit Over Alleged Dental Injuries

    Executives and directors of dental supply manufacturing company Dentsply Sirona Inc. have been hit with a derivative suit alleging they concealed that a company subsidiary was approving unsuitable patients for dental treatments to inflate sales figures.

Expert Analysis

  • How To Accelerate Your Post-Attorney Career Transition

    Author Photo

    Professionals seeking to transition to nonattorney careers may encounter skepticism as nontraditional candidates, but there are opportunities for thought leadership and to leverage speaking and writing to accelerate a post-attorney career transition, say Janet Falk at Falk Communications and Evgeny Efremkin at Toronto Metropolitan University.

  • 5 Key Licensing Considerations For AI Innovations

    Author Photo

    As businesses increasingly integrate artificial intelligence technology into their operations, they must prepare to address complex intellectual property challenges and questions surrounding licensing AI-based innovations, which require careful consideration of ownership, usage rights and regulatory compliance, says Lestin Kenton at Sterne Kessler.

  • A Higher Bar For Expert Witnesses In Drug Patent Litigation

    Author Photo

    With recent decisions emphasizing courts' growing insistence on robust methodologies in pharmaceutical patent disputes, litigators must be strategic in how they utilize expert testimony and adapt to venue-specific expectations, says Jeremy Scholem at WIT Legal.

  • Series

    Law School's Missed Lessons: Be An Indispensable Associate

    Author Photo

    While law school teaches you to research, write and think critically, it often overlooks the professional skills you will need to make yourself an essential team player when transitioning from a summer to full-time associate, say attorneys at Stinson.

  • Series

    Birding Makes Me A Better Lawyer

    Author Photo

    Observing and documenting birds in their natural habitats fosters patience, sharpens observational skills and provides moments of pure wonder — qualities that foster personal growth and enrich my legal career, says Allison Raley at Arnall Golden.

  • Series

    Adapting To Private Practice: From DOJ Leadership To BigLaw

    Author Photo

    The move from government service to private practice can feel like changing one’s identity, but as someone who has left the U.S. Department of Justice twice, I’ve learned that a successful transition requires patience, effort and the realization that the rewards of practicing law don’t come from one particular position, says Richard Donoghue at Pillsbury.

  • Fed. Circ. Ruling Reaffirms Listing Elements Separately Is Key

    Author Photo

    The Federal Circuit's decision last month in Regeneron v. Mylan reaffirms a critical principle in patent law: When a claim lists elements separately, the clear implication is that they are distinct elements, say attorneys at Taft.

  • State Extended Producer Responsibility Laws: Tips For Cos.

    Author Photo

    As states increasingly shift the onus of end-of-life product management from consumers and local governments to the businesses that produce, distribute or sell certain items, companies must track the changing landscape and evaluate the applicability of these new laws and regulations to their operations, say attorneys at Alston & Bird.

  • Law Firm Executive Orders Create A Legal Ethics Minefield

    Author Photo

    Recent executive orders targeting BigLaw firms create ethical dilemmas — and raise the specter of civil or criminal liability — for the government attorneys tasked with implementing them and for the law firms that choose to make agreements with the administration, say attorneys at Buchalter.

  • Firms Must Embrace Alternative Billing Models Or Fall Behind

    Author Photo

    As artificial intelligence tools eliminate inefficiencies and the Big Four accounting firms enter the legal market, law firms that pivot from the entrenched billable hour model to outcomes-based pricing will see a distinct competitive advantage, says attorney William Brewer.

  • Key Issues To Watch As USPTO Changes Abound

    Author Photo

    As 2025 continues to unfold, changes at the U.S. Patent and Trademark Office — including new leadership, operational reforms, legislative initiatives and AI-related policies — have potential to influence proceedings, including efforts to prosecute patents and adversarial proceedings before the Patent Trial and Appeal Board, say attorneys at Morgan Lewis.

  • Trending At The PTAB: A Pivot On Discretionary Denials

    Author Photo

    Following the U.S. Patent and Trademark Office's rescission of the 2022 Vidal memorandum and a reversion to the standards under Apple v. Fintiv, petitioners hoping to avoid discretionary denials should undertake holistic review of all Fintiv factors, rather than relying on certain fail-safe provisions, say attorneys at Finnegan.

  • How Attorneys Can Master The Art Of On-Camera Presence

    Author Photo

    As attorneys are increasingly presented with on-camera opportunities, they can adapt their traditional legal skills for video contexts — such as virtual client meetings, marketing content or media interviews — by understanding the medium and making intentional adjustments, says Kerry Barrett.

  • Patent Drafting Pointers From Fed. Circ. COVID Test Ruling

    Author Photo

    The Federal Circuit's recent decision in DNA Genotek v. Spectrum Solutions provides several best practice pointers for drafting and prosecuting patent applications, highlighting how nuances in wording can potentially limit the scope of claims or otherwise affect claim constructions, says Irah Donner at Manatt.

  • Opinion

    Congress Must Reform The PTAB To Protect Small Innovators

    Author Photo

    Lawmakers must reintroduce the Promoting and Respecting Economically Vital American Innovation Leadership Act or similar legislation to prevent larger companies from leveraging the Patent Trial and Appeal Board to target smaller patent holders, says Schwegman Lundberg's Russell Slifer, former deputy director of the U.S. Patent and Trademark Office.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!